Abstract:OBJECTIVE:To explore the clinical significance of the combined detection of Clara cell secretory protein 16 (CC16) and soluble receptor for advanced glycation end product (sRAGE) in the diagnosis and prognosis of acute respiratory distress syndrome (ARDS).METHODS:100 ARDS patients admitted to the intensive care unit (ICU) of Chu Hsien-I Memorial Hospital of Tianjin Medical University from July 2019 to September 2020 were enrolled as the ARDS group, and 100 non-ARDS patients admitted to the ICU during the same period were enrolled as the control group. The general information, vital signs, blood gas analysis, serum CC16 and sRAGE levels, duration of mechanical ventilation, length of ICU stay and prognosis during hospitalization were collected. The receiver operating characteristic (ROC) curve was drawn and the area under ROC curve (AUC) was calculated to evaluate the clinical value of CC16 and sRAGE lonely or combination in the diagnosis and prognosis of ARDS.RESULTS:The duration of mechanical ventilation in the ARDS group was significantly longer than that in the non-ARDS group (days: 15.44±3.04 vs. 12.61±3.73, P < 0.01), and the hospitalization mortality was higher (38.0% vs. 9.0%, P < 0.01), but there was no significant difference in gender, age, body mass index (BMI), acute physiology and chronic health evaluation II (APACHE II) score or the length of ICU stay between the two groups. There were 62 ARDS patients survived and 38 ARDS patients died during hospitalization. The APACHE II score of the death group was significantly higher than that of the survival group (23.55±2.83 vs. 19.40±4.10, P < 0.01), but there was no significant difference in age, BMI, oxygenation index, mean arterial pressure, duration of mechanical ventilation or the length of ICU stay between the two groups. The serum levels of CC16 and sRAGE in the ARDS group were significantly higher than those in the non-ARDS group [CC16 (mg/L): 38.78±14.70 vs. 21.87±2.45, sRAGE (pg/L): 2 470.95±288.70 vs. 2 013.22±131.15, both P < 0.01]; and the serum levels of CC16 and sRAGE of ARDS patients in the death group were significantly higher than those in the survival group [CC16 (mg/L): 42.02±10.81 vs. 30.52±9.47, sRAGE (pg/L): 2 638.34±324.07 vs. 2 279.91±163.70, both P < 0.01]. ROC curve showed that the AUC of CC16 and sRAGE in the diagnosis of ARDS alone were 0.859 [95% confidence interval (95%CI) was 0.808-0.911] and 0.821 (95%CI was 0.762-0.879), and the best cut-off values were 25.76 mg/L and 2 203.00 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.932 (95%CI was 0.900-0.965) with the sensitivity of 89.0% and the specificity of 87.6%. The AUC of CC16 and sRAGE in predicting the death of patients with ARDS during hospitalization were 0.747 (95%CI was 0.651-0.843) and 0.819 (95%CI was 0.737-0.902), and the best cut-off values were 32.95 mg/L and 2 554.50 pg/L, respectively; the AUC of combined detection of CC16 and sRAGE was 0.900 (95%CI was 0.828-0.972) with the sensitivity of 88.7% and the specificity of 84.5%.CONCLUSIONS:Serum CC16 and sRAGE have clinical value for the diagnosis and prognosis of ARDS. The combined detection of them is superior to individual detection for early prediction of ARDS and prognosis.

Elevated soluble death receptor 5 can predict poor prognosis in patients with acute respiratory distress syndrome

The Diagnostic Value of Soluble Death Receptor 5 in ARDS

Mir-584 and Mir-146 Are Candidate Biomarkers for Acute Respiratory Distress Syndrome

The Relationship Between Soluble Cd74, Scd14 And Severity And Prognosis In Patients With Acute Respiratory Distress Syndrome

Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

A Preliminary Study on the Relationship Between the Levels of Plasma TRAIL and DR5 and Acute Coronary Syndrome

Developing a predictive nomogram for mortality in patients with extrapulmonary acute respiratory distress syndrome: the prognostic value of serum soluble thrombomodulin, lung ultrasound score, and lactate

Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics

Thrombocytopenia Is Associated With Acute Respiratory Distress Syndrome Mortality: An International Study

[Significance of Combined Application of Biomarkers in the Diagnosis and Prognosis Assessment of Patients with Acute Respiratory Distress Syndrome].

Prognostic Value of Angiopoietin-like 4 in Patients with Acute Respiratory Distress Syndrome

Serum CD5L predicts acute lung parenchymal injury and acute respiratory distress syndrome in trauma patients

TM9SF1 offers utility as an efficient predictor of clinical severity and mortality among acute respiratory distress syndrome patients

Serological ferritin, 100A12, procalcitonin and APACHEII score in prediction the prognosis of acute respiratory distress syndrome

Lung Fluid Biomarkers for Acute Respiratory Distress Syndrome: a Systematic Review and Meta-Analysis

Prognosis risk factors in patients with acute respiratory distress syndrome caused by thrombocytopenia

A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

Prognostic Value of Secretory Autophagosomes in Patients with Acute Respiratory Distress Syndrome

Predictive Value of Plasma Sicam-1 and Sp-Selectins in the Risk of Death in Patients with Acute Respiratory Distress Syndrome.

Blocking TRAIL-DR5 signaling pathway with soluble death receptor 5 fusion protein mitigates radiation-induced injury

TRAIL and DR5 contribute to the development of atherosclerosis